Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Perinat Neonatal Nurs ; 37(4): 325-331, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37115978

RESUMO

Late-onset hyponatremia (LOH) frequently affects premature infants 2 or more weeks of age due to inadequate sodium intake and excessive kidney loss. Late-onset hyponatremia typically occurs in infants who are physiologically stable and is defined as serum sodium of 132 mEq/L or less or between 133 and 135 mEq/L if receiving sodium supplementation. Recent evidence suggests that spot urine sodium levels may improve the recognition of LOH, as low levels of excreted urine reflect a total body sodium deficit and negative balance. Untreated LOH may result in poor somatic growth, neurodevelopmental delay, higher incidence of bronchopulmonary dysplasia, and more severe retinopathy of prematurity. The primary prevention of LOH is to maintain serum sodium between 135 and 145 mEq/L; however, there are currently no formal protocols guiding sodium supplementation. The purpose of this article is to present on overview of LOH pathophysiology and its effect on somatic growth, neurodevelopment outcomes, and other related sequelae. We further discuss general management strategies and describe a protocol for sodium supplementation that is presently undergoing an evaluation for effectiveness.


Assuntos
Displasia Broncopulmonar , Hiponatremia , Humanos , Lactente , Recém-Nascido , Hiponatremia/diagnóstico , Hiponatremia/etiologia , Hiponatremia/terapia , Recém-Nascido Prematuro , Sódio
2.
Vaccine ; 34(30): 3443-6, 2016 06 24.
Artigo em Inglês | MEDLINE | ID: mdl-27195761

RESUMO

We compared ≥4-fold increases in antibody titers by hemagglutination inhibition assay to RT-PCR results among 42 adults with PCR-confirmed influenza A virus illnesses. Serologic sensitivity was higher among unvaccinated (69%, 95% confidence interval [CI]=48-90%) than vaccinated healthcare personnel (38%, 95% CI=29-46%) in a 2010-11 prospective cohort.


Assuntos
Anticorpos Antivirais/sangue , Vacinas contra Influenza/uso terapêutico , Influenza Humana/prevenção & controle , Adulto , Feminino , Pessoal de Saúde , Testes de Inibição da Hemaglutinação , Humanos , Vírus da Influenza A Subtipo H3N2 , Vírus da Influenza A , Modelos Lineares , Masculino , Estudos Prospectivos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sensibilidade e Especificidade , Vacinas de Produtos Inativados/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...